Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

874 Press Releases
DateTitleCompany
15 Jun 15 Merck Millipore Expands Provantage® Biodevelopment Services with Addition of Provantage® Clone Generation Service Merck ,
Published by
PharmiWeb.com
15 Jun 15 Merck Millipore Introduces the Mobius® 2000 Liter Single-Use Bioreactor with Industry-leading Design for Ease-of-Use Merck ,
Published by
PharmiWeb.com
11 Jun 15 Merck Launches New Program That Encourages Women to “Rule the Real Talk” and Prioritize Their Sexual Health Merck,
Published by
PharmiWeb.com
11 Jun 15 Merck Serono Wins Two Red Dot Design Awards 2015 for High Quality Design of Fertility Pens Merck,
Published by
PharmiWeb.com
10 Jun 15 Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints Merck,
Published by
PharmiWeb.com
10 Jun 15 Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4 Enbrel (Etanercept) and SB2 Remicade (Infliximab) Met Primary Endpoints Merck,
Published by
Business Wire
10 Jun 15 New Data on Quality-of-Life Benefits of SIMPONI® (Golimumab) in Treating Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axial SpA) Merck Sharp and Dohme
09 Jun 15 TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes Merck ,
Published by
PharmiWeb.com
09 Jun 15 Consumerization Drives Growth at Merck Consumer Health Merck,
Published by
Business Wire
08 Jun 15 TECOS Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin) Met Primary Endpoint in Patients with Type 2 Diabetes Merck,
Published by
Business Wire
08 Jun 15 Merck, Illumina and Genea Form the Global Fertility Alliance for Excellence in Assisted Reproductive Treatment Merck,
Published by
PharmiWeb.com
08 Jun 15 Merck's KEYTRUDA™ (pembrolizumab) receives conditional approval in Canada for the treatment of advanced melanoma Merck Canada Inc.,
Published by
PR Newswire
03 Jun 15 CORRECTING and REPLACING CAPTION Merck KGaA Darmstadt Germany Celebrates 125 Years in the U.S. with Launch of “Smarter Together” Initiative Merck KGaA,
Published by
Business Wire
03 Jun 15 Merck KGaA Darmstadt Germany Celebrates 125 Years in the U.S. with Launch of “Smarter Together” Initiative Merck KGaA,
Published by
Business Wire
01 Jun 15 FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) Merck’s Anti-PD-1 Therapy in Advanced Non-Small Cell Lung Cancer and Grants Priority Review Merck,
Published by
Business Wire
01 Jun 15 Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies Merck,
Published by
Business Wire
29 May 15 New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab) Merck’s Anti-PD-1 Therapy in Patients with Advanced Head and Neck Cancer Regardless of PD-L1 Expression Status Merck,
Published by
Business Wire
28 May 15 Merck Submits U.S. New Drug Application for Grazoprevir/Elbasvir an Investigational Once-Daily Single Tablet Combination Therapy for Treatment of Chronic Hepatitis C Genotypes 1 4 and 6 Infection Merck,
Published by
Business Wire
21 Apr 15 Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress Merck,
Published by
Business Wire
28 May 15 Merck Serono as Pioneer in Assisted Reproductive Treatments Takes Leading Role in Fertility Technologies Signing a Global Collaboration Agreement with Genea Biomedx Merck Serono,
Published by
PR Newswire
28 May 15 Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab) Merck,
Published by
Business Wire
26 May 15 Merck Announces Third-Quarter 2015 Dividend Merck,
Published by
Business Wire
14 May 15 Merck KGaA Darmstadt Germany and Pfizer to Present Data at ASCO for Avelumab an Investigational Anti-PD-L1 Antibody Pfizer Inc. and Merck KGaA, Darmstadt, Germany,
Published by
Business Wire
22 May 15 Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma Merck,
Published by
Business Wire
21 May 15 Merck Millipore Enters Into Agreement to Acquire Exclusive Rights to Singulex's Ultra-Sensitive Single Molecule Counting (SMC™) Technology Merck Millipore,
Published by
PR Newswire
24 Apr 15 Merck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection Merck,
Published by
Business Wire
28 Apr 15 Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA™ (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases Merck,
Published by
Business Wire
28 Apr 15 Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint Merck,
Published by
Business Wire
23 Apr 15 Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease Merck,
Published by
Business Wire
23 Apr 15 Merck Millipore Introduces Magna ChIRP™ RNA Interactome Kits for the Analysis of Chromatin-Associated RNAs Merck Millipore,
Published by
PR Newswire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.